Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall

  • 📰 nbcsandiego
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 51%

News News

Business Business Latest News,Business Business Headlines

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. 

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.

The pharmaceutical giant narrowed its full-year sales forecast to a range of $63.6 billion to $64.1 billion, from a previous guidance of $63.4 billion to $64.4 billion.Merck also lowered its adjusted profit guidance from a range of $7.72 to $7.77 per share, from a previous forecast of $7.94 to $8.04 per share. That updated outlook reflects a one-time charge of 24 cents per share related to business development deals with Curon Biopharmaceutical and Daiichi Sankyo.Merck posted net income of $3.

But Merck has a handful of new deals under its belt and key drug launches that will help it offset those losses. That includesAnd Capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and lung infection, was approved in the U.S. in June.Merck's pharmaceutical division, which develops a wide range of drugs, booked $14.94 billion in revenue during the third quarter, up 5% from the same period a year ago.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 524. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

3 Bargain Stocks Positioned for Gains After Missing 2024’s RallyStocks Analysis by MarketBeat.com (Leo Miller) covering: S&P 500, Merck & Company Inc, Adobe Systems Incorporated, Applied Materials Inc. Read MarketBeat.com (Leo Miller)'s latest article on Investing.com
Source: Investingcom - 🏆 450. / 53 Read more »